House to CMS: Don’t treat biosimilars like generics
A group of House leaders are taking issue with the way CMS (Centers for Medicare & Medicaid Services) has laid out plans to reimburse for biosimilars, according to a letter 30 members of Congress sent to CMS’ acting administrator last week.